The therapeutic use of A2A adenosine receptor (AR) antagonists for the treatment of neurodegenerative disorders, such as Parkinson and Alzheimer diseases, is a very promising approach. This evidence concerns the gene AR and early-onset autosomal dominant Alzheimer disease.